Author
We publish evidence-based peptide guides focused on mechanisms, human evidence, regulatory status, side effects, sourcing risks and practical comparisons.
Nasal peptide sprays are popular because they avoid needles, but intranasal delivery is peptide-specific. Regulated products and wellness sprays should not be treated as the same category.
Most peptides do not survive the gut well enough to work as ordinary pills. A few oral peptide medicines work because their chemistry, enhancer system, or local gut target is unusual.
Gut peptide claims range from approved oral GI drugs to research-only BPC-157 and KPV. The evidence depends on route, target and endpoint.
Skin peptides range from oral collagen and topical Matrixyl to Argireline, GHK-Cu, PDRN and glutathione. The evidence is useful but uneven.
Current guidance no longer treats every GLP-1 user the same before surgery. Risk depends on symptoms, dose escalation, procedure type and anesthesia plan.
A peptide COA can answer a narrow lab question. It cannot prove clinical evidence, safe human use, legal status, sterility or correct dosing by itself.
Abaloparatide is an FDA-approved PTHrP(1-34) analog peptide that builds bone in high-risk osteoporosis, backed by the ACTIVE and ATOM trials with clear duration and safety limits.
ACE-031 is not a classic peptide but an ActRIIB-Fc decoy receptor that traps myostatin and activin. Early trials showed muscle gains, but development was halted over vascular safety signals.
Adipotide is a research-only pro-apoptotic peptidomimetic that targeted fat-vessel prohibitin in animals but was abandoned in humans over kidney toxicity.